Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism

Brain Research

Volumn 839, Issue 1, 1999, Pages 190-193

  Jimenez A ^a   Marin, C ^a   Bonastre, M ^a   Tolosa, E ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

6 Hydroxydopamine; Dextromethorphan; Levodopa; Motor fluctuation; Rotation

Indexed keywords

DEXTROMETHORPHAN; LEVODOPA; OXIDOPAMINE;

ANIMAL MODEL; ARTICLE; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOTOR ACTIVITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; DEXTROMETHORPHAN; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; TREATMENT OUTCOME;

EID: 0344069774     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01657-1     Document Type: Article

References (20)

1. Bonuccelli U., Del Dotto P., Piccini P., Behgé F., Corsini G.U., Muratorio A. Dextromethorphan and parkinsonism. Lancet. 340:1992;53.
2. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 50:1998;S17-S25. Suppl. 5.
3. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology. 51:1998;S30-S35. Suppl. 2.
4. Choi D.W. Dexthorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res. 403:1987;333-336.
5. Engber T.M., Chase T.N. Dextromethorphan does not protect against quinolinic acid neurotoxicity in rat striatum. Neurosci. Lett. 95:1988;269-274.
6. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586-2588.
7. Kaur S., Starr M.S. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur. J. Pharmacol. 280:1995;159-166.
8. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann. Neurol. 28:1990;536-539.
9. Klockgether T., Turski K., Honore T.et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30:1991;717-723.
10. Lipton S.A. Prospects for clinically tolerated NMDA antagonists: open channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 16:1993;527-532.
11. Löschman P.A., Lange K.W., Kunow M., Rettig K.J., Jähnig P., Honoré P., Turski T., Wachtel H., Jenner P., Marsden C.D. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J. Neural Transm.: Parkinson's Dis. Dementia Sect. 3:1991;203-213.
12. Marin C., Papa S., Engber M., Bonastre M., Tolosa E., Chase T.N. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
13. Marin C., Bonastre M., Chase T.N., Tolosa E. Reversal of levodopa-induced motor response alterations by NMDA and non-NMDA glutamate receptor antagonists. Mov. Disord. 12:1997;138.
14. Montrastuc J.L., Fabre N., Rascol O., Senard J.M. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan. Mov. Disord. 9:1994;242-243.
15. Papa S.M., Engber T.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
16. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
17. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1986.
18. Saenz R., Tanner C.M., Albers G., Kurth G., Tetrud J. A preliminary study of dextromethorphan as adjunctive therapy in Parkinson's disease? Neurology. 43:1993;A115.
19. Turski L., Bressler K., Löschamnn P.A., Watchel H. Protection of substantia nigra from MPP+neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
20. Verhagen Metman L., Blanchet P.J., Van den Munchof P., Del Dotto P., Natté R., Chase T.N. A trial of dextromethorphan in parkinsonian patients with motor responses complications. Mov. Disord. 13:1998;414-417.